TrialSignal
Clinical trial intelligence report
Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01417065-Jul 28, 2026
NCT ID
NCT01417065
Status
COMPLETED
Phase
EARLY_PHASE1
Sponsor
M.D. Anderson Cancer Center
Executive brief
Investment-Ready Snapshot
Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets is a EARLY_PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Advanced Cancer. SEO and diligence focus: Temsirolimus, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01417065
Indication
Advanced Cancer
Modality
small molecule
Target
Temsirolimus
Intervention
Temsirolimus
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.